OverviewSuggest Edit

Kiadis Pharma is a biopharmaceutical company focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients addressing high-unmet medical needs. Kiadis Pharma is headquartered in Amsterdam, The Netherlands.
TypePublic
Founded1997
HQAmsterdam, NL
Websitekiadis.com

Latest Updates

Employees (est.) (May 2021)103(-39%)
Share Price (May 2021)€5.5
Cybersecurity ratingBMore

Key People/Management at Kiadis Pharma

Robert Friesen

Robert Friesen

Chief Scientific Officer
Robert Soiffer

Robert Soiffer

Supervisory Board Member
Martine Nolan

Martine Nolan

Senior Vice President, Quality
Andrew Sandler

Andrew Sandler

Chief Medical Officer
Show more

Kiadis Pharma Office Locations

Kiadis Pharma has an office in Amsterdam
Amsterdam, NL (HQ)
Paasheuvelweg 25a
Show all (1)

Kiadis Pharma Financials and Metrics

Kiadis Pharma Revenue

Market capitalization (24-May-2021)

218.6m

Closing stock price (24-May-2021)

5.5
Kiadis Pharma's current market capitalization is €218.6 m.
Show all financial metrics

Kiadis Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Kiadis Pharma Online and Social Media Presence

Embed Graph

Kiadis Pharma News and Updates

Kiadis Pharma announces abstract accepted for presentation at the 2020 ISCT Annual Meeting

Amsterdam, The Netherlands, May 25, 2020 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces an abstract highlighting data related to the Company’s natural killer (NK) cell therapy program has bee…

Kiadis Pharma files first investigational new drug application with the U.S. FDA for natural killer (NK) cell therapy produced with PM21

                                               Kiadis Pharma files first investigational new drug application with the U.S. FDA for natural killer (NK) cell therapy produced with PM21

Kiadis Pharma to present at BioCapital Europe 2020

Amsterdam, The Netherlands, March 4, 2020 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that Arthur Lahr, chief executive officer, will present at BioCapital Europe 2020 in Amsterdam on Thur…

Kiadis Pharma announces FDA clearance of clinical study by The Ohio State University in R/R AML with off-the-shelf NK cells from universal donors

Amsterdam, The Netherlands, February 26, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, and The Ohio State University - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (“OSU” or “OSUCC…

Kiadis Pharma announces formation of renowned Scientific Advisory Board

Amsterdam, The Netherlands, 22 October 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces the formation of its Scientific Advisory Board (SAB) comprised of world-leading experts in the field…
Show more

Kiadis Pharma Blogs

Conversion of Kiadis to a private limited liability company postponed until completion of statutory buy-out proceedings

This is a joint press release by Sanofi Foreign Participations B.V. (the “ Offeror ”), Sanofi (“ Sanofi ”) and Kiadis Pharma N.V. (“ Kiadis ”) in connection with the recommended public offer by the Offeror for all the issued and outstanding ordinary shares in the capital of Kiadis (the “ Offer ”).

Notice of Annual General Meeting of Shareholders

Notice of Annual General Meeting of Shareholders Content Import Thu, 05/13/2021 - 11:45 Notice of Annual General Meeting of Shareholders May 13, 2021 at 11:45 AM EDT This release is a backfill from a News Wire Investors …

Final results of the Offer for Kiadis: 97.39% of Kiadis Shares in total committed under the Offer

Final results of the Offer for Kiadis: 97.39% of Kiadis Shares in total committed under the Offer Content Import Thu, 04/29/2021 - 01:00 Final results of the Offer for Kiadis: 97.39% of Kiadis Shares in total committed under the Offer April 29, 2021 at 1:00 AM EDT …

Delisting of Kiadis will be effective on 25 May 2021

Delisting of Kiadis will be effective on 25 May 2021 Content Import Mon, 04/26/2021 - 12:03 Delisting of Kiadis will be effective on 25 May 2021 April 26, 2021 at 12:02 PM EDT This release is a backfill from a News Wire Investors …

Kiadis Pharma announces annual results for the year ended December 31, 2020

New strategic focus results in significant progress in cell based therapies Amsterdam, The Netherlands, April 7, 2021 – Kiadis Pharma N.V. (“Kiadis”, “Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS) , a clinical-stage

Kiadis Shareholders give irrevocable commitment to tender 36.6% of the shares under the offer by Sanofi

This is a joint press release by Sanofi (" Sanofi ") and Kiadis Pharma N.V. (" Kiadis "), pursuant to the provisions of Sections 5 paragraphs 4 and 5 and Section 6 paragraph 2 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the “Decree” ) in connection with the
Show more

Kiadis Pharma Frequently Asked Questions

  • When was Kiadis Pharma founded?

    Kiadis Pharma was founded in 1997.

  • Who are Kiadis Pharma key executives?

    Kiadis Pharma's key executives are Robert Friesen, Robert Soiffer and Martine Nolan.

  • How many employees does Kiadis Pharma have?

    Kiadis Pharma has 103 employees.

  • Who are Kiadis Pharma competitors?

    Competitors of Kiadis Pharma include Libbs Farmaceutica, USV and Aurobindo Pharma.

  • Where is Kiadis Pharma headquarters?

    Kiadis Pharma headquarters is located at Paasheuvelweg 25a, Amsterdam.

  • Where are Kiadis Pharma offices?

    Kiadis Pharma has an office in Amsterdam.

  • How many offices does Kiadis Pharma have?

    Kiadis Pharma has 1 office.